Your genes may decide if metformin works for you

NCT ID NCT07760883

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study is looking at whether a specific genetic variation, called SLC16A11, influences how well the common diabetes drug metformin lowers blood sugar. Adults with type 2 diabetes will be grouped by whether they carry this gene variant and will take extended-release metformin for six months. Researchers will compare changes in HbA1c (a long-term blood sugar measure) and other health markers between the two groups. The goal is to see if genetic information could help personalize diabetes treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Metformin (extended-release)
What this could lead to
If successful, this could help doctors tailor metformin treatment based on a person's genetic makeup, improving blood sugar control for those with type 2 diabetes.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to all populations, and genetic testing may not be widely available in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

    RECRUITING

    Mexico City, Mexico City, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.